LETTER
Stereoselective Approach to Multi-Functionalized Oxetanes
653
(7) (a) Trost, B. M.; Edstrom, E. D. Angew. Chem., Int. Ed.
Engl. 1990, 29, 520. (b) Tomooka, K.; Nakamura, Y.;
References
(1) Reviews: (a) Porco, J. A.; Schreiber, S. L. In Comprehensive
Organic Synthesis, Vol. 5; Trost, B. M.; Fleming, I., Eds.;
Pergamon: Oxford, 1991, 151–192. (b) Abe, M.; Nojima,
M. J. Synth. Org. Chem., Jpn. 2001, 59, 855.
(2) For example: (a) Thromboxane A2: Bhalgwat, S. S.; Still,
W. C. J. Am. Chem. Soc. 1985, 107, 6372. (b) Oxetin:
Kawata, Y.; Ikekawa, N.; Murata, M.; Omura, S. Chem.
Pharm. Bull. 1986, 34, 3102. (c) Oxetanocin: Nishiyama,
S.; Yamamura, S. J. Synth. Org. Chem., Jpn. 1991, 49, 670.
(d) Merrilactone A: Birman, V. B.; Danishefsky, S. J. J. Am.
Chem. Soc. 2002, 124, 2080.
Nakai, T. Synlett 1995, 321.
(8) Crystallographic data of 4a and 2b have been deposited with
the Cambridge Crystallographic Data Center as
supplementary publication no. CCDC 225890 and 225891,
respectively. Copies of the data can be obtained free of
charge on application to CCDC, 12 Union Road, Cambridge
CB21EZ, UK [fax: +44 (1223)336033; e-mail:
deposit @ccdc.cam.ac.uk].
(9) The relative stereochemistry of 2c was determined by NOE
experiment of its acetal derivative as shown below
(Scheme 9).
(3) (a) Tomooka, K.; Yamamoto, H.; Nakai, T. J. Am. Chem.
Soc. 1996, 118, 3317. (b) Tomooka, K.; Yamamoto, H.;
Nakai, T. Angew. Chem. Int. Ed. 2000, 39, 4500.
(4) All new compounds were fully characterized by IR, 1H and
13C NMR analyses. Data for selected compounds are as
follows. Compound a-1a: 1H NMR (300 MHz, CDCl3): d =
7.55–7.52 (m, 2 H), 7.40–7.38 (m, 3 H), 5.98 (d, J = 3.9 Hz,
1 H), 5.85 (s, 1 H), 4.13 (d, J = 3.9 Hz, 1 H), 3.84 (d, J = 8.1
Hz, 1 H), 3.54 (d, J = 8.1 Hz, 1 H), 1.14 (s, 3 H), 1.07 (s, 3
H). 13C NMR (75 MHz, CDCl3): d = 137.0, 129.6, 128.4,
126.7, 106.2, 104.7, 88.0, 77.2, 43.0, 24.0, 17.9. Compound
b-1a: 1H NMR (300 MHz, CDCl3): d = 7.48–7.44 (m, 2 H),
7.40–7.37 (m, 3 H), 6.09 (s, 1 H), 6.03 (d, J = 3.6 Hz, 1 H),
4.23 (d, J = 3.6 Hz, 1 H), 3.78 (d, J = 8.6 Hz, 1 H), 3.69 (d,
J = 8.6 Hz, 1 H), 1.20 (s, 3 H), 1.07 (s, 3 H). 13C NMR (75
MHz, CDCl3): d = 137.5, 129.5, 128.4, 126.4, 106.0, 105.7,
88.1, 80.1, 43.0, 25.0, 18.9. IR (neat): 2963, 2873, 1460,
1393, 1222, 1074, 1027, 1008 cm–1. Anal. Calcd for
Scheme 9
(10) The substrate 2d consisted of a 1:1 mixture of two epimers
at the chirality center of s-Bu.
(11) General Procedure for the Ring-Contraction Reaction:
To a THF (9 mL) solution of 1a (72.4 mg, 0.33 mmol, 62%
dr) was added n-BuLi (1.04 mL, 1.27 M in hexane, 1.32
mmol) dropwise at –78 °C. After the addition, the solution
was stirred for 15 min at –78 °C, and the temperature was
allowed to rise to 0 °C over a period of 1 h. The resulting
mixture was stirred at 0 °C for 1 h, and then sat. NH4Cl aq
was added. The mixture was extracted with Et2O. The
combined organic phase was dried over Na2SO4, filtered and
the solvent was removed in vacuo. The residue was purified
by silica gel column chromatography (hexane/Et2O = 1:1) to
give the oxetane 2c (67.8 mg, 74%, >95% dr). In the case of
the reaction with MeLi, >10 equiv of MeLi was required to
drive the reaction to completion.
28
C13H16O3: C, 70.89; H, 7.32. Found: C, 71.16; H, 7.26. [a]D
+29.4 (c 3.67, CHCl3). Compound 2a: 1H NMR (300 MHz,
CDCl3): d = 7.61 (d, J = 7.8 Hz, 1 H), 7.41–7.36 (m, 1 H),
7.26–7.25 (m, 3 H), 5.10 (br s, 1 H), 4.92 (d, J = 7.4 Hz, 1
H), 4.44 (d, J = 7.4 Hz, 1 H), 3.63 (d, J = 10.4 Hz, 1 H), 3.00
(d, J = 10.4 Hz, 1 H), 1.60 (br s, 1 H), 0.96 (s, 12 H), 0.84 (s,
3 H). 13C NMR (75 MHz, CDCl3): d = 139.2, 128.8, 127.6,
127.2, 126.5, 125.9, 95.9, 88.7, 70.0, 66.7, 39.4, 37.4, 24.7,
24.4, 19.8. IR (reflection): 3235, 2925, 1473, 1391, 1364,
1169, 963, 709, 598 cm–1. Compound 2e: 1H NMR (300
MHz, CDCl3): d = 4.26 (d, J = 7.0 Hz, 1 H), 4.16 (dd,
J = 11.3, 7.0 Hz, 1 H), 3.55 (d, J = 11.1 Hz, 1 H), 3.40 (dd,
J = 11.1, 5.3 Hz, 1 H), 2.60 (d, J = 11.3 Hz, 1 H), 2.09 (br s,
1 H), 1.63 (s, 3 H), 0.99 (s, 3 H), 0.97 (s, 9 H), 0.93 (s, 3 H),
0.19 (s, 6 H). 13C NMR (75 MHz, CDCl3): d = 103.0, 95.1,
94.1, 82.8, 72.1, 70.0, 37.3, 26.5, 26.2, 20.0, 19.4, 16.6, –
4.39, –4.44. IR (neat): 3418, 2956, 2928, 2857, 1472, 1363,
1251, 1123, 835, 777 cm–1. Compound 6: 1H NMR (300
MHz, CDCl3): d = 7.43–7.29 (m, 5 H), 5.89 (br s, 1 H), 5.45
(dd, J = 2.7, 2.4 Hz, 1 H), 4.56 (br s, 2 H), 4.04 (d, J = 10.5
Hz, 1 H), 3.43 (d, J = 10.5 Hz, 1 H), 1.74 (br s, 1 H), 1.10 (s,
3 H), 1.01 (s, 3 H). 13C NMR (75 MHz, CDCl3): d = 141.0,
128.6, 128.3, 128.1, 125.5, 125.3, 91.4, 90.8, 74.4, 66.6,
39.6, 23.5, 20.2. IR (neat): 3332, 2958, 2929, 1454, 1134,
1047, 972, 698 cm–1.
(12) Acetal 1b was prepared from (–)-pantolactone in three steps
as shown below (Scheme 10).
Scheme 10
(5) The diastereomer ratio was determined by 1H NMR analysis.
(6) The relative stereochemistry of a-1a and 2e was determined
by NOE experiment as shown below (Figure 2).
(13) We cannot rule out the possibility that the reaction proceeds
via not a free carbene but a related carbenoid intermediate.
(14) The alkyl lithium-promoted carbene or a related carbenoid
formation in acetal system, followed by its insertion to alkyl
lithium has been reported, see: (a) Shiner, C. S.; Tsunoda,
T.; Goodman, B. A.; Ingham, S.; Lee, S.; Vorndam, P. E. J.
Am. Chem. Soc. 1989, 111, 1381. (b) Boche, G.; Bosold, F.;
Lohrenz, J. C. W.; Opel, A.; Zulauf, P. Chem. Ber. 1993,
126, 1873.
Figure 2
Synlett 2004, No. 4, 651–654 © Thieme Stuttgart · New York